IOTA PHARMACEUTICALS LTD
Desconocido
GENIALG: GENetic diversity exploitation for Innovative macro ALGal biorefinery
IOTA Pharmaceuticals Ltd
participó en un
H2020:
H2020-BG-2016-2017
The GENIALG project aims to boost the Blue Biotechnology Economy (BBE) by increasing the production and sustainable exploitation of two high...
2016-10-13 - 2021-06-30 | Financiado
2016-10-13 - 2021-06-30 | Financiado
FRAGNET: FRAGments training NETwork
IOTA Pharmaceuticals Ltd
participó en un
H2020:
H2020-MSCA-ITN-2015
The promise of more efficient lead discovery is fuelling the enthusiasm for fragment-based lead discovery (FBLD). In this approach, highly s...
2015-08-11 - 2020-02-29 | Financiado
2015-08-11 - 2020-02-29 | Financiado
PDE4NPD: Parasite specific cyclic nucleotide phosphodiesterase inhibitors to target Neglected Parasitic Disea...
IOTA Pharmaceuticals Ltd
participó en un
FP7:
This project aims to unite global efforts to target the highly druggable class of enzymes called cyclic nucleotide phosphodiesterases (PDEs)...
Financiado
Financiado
* No se disponen de datos de la empresa actual.